Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Hyperparathyroidism
ADR ID BADD_A02134
ADR Hierarchy
05      Endocrine disorders
05.04      Parathyroid gland disorders
05.04.01      Hyperparathyroid disorders
05.04.01.001      Hyperparathyroidism
14      Metabolism and nutrition disorders
14.04      Bone, calcium, magnesium and phosphorus metabolism disorders
14.04.01      Calcium metabolism disorders
14.04.01.020      Hyperparathyroidism
Description A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood). [CTCAE] A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES. [MeSH]
MedDRA Code 10020705
MeSH ID D006961
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Hyperparathyroidism | Hyperparathyroidism NOS | Normocalcaemic hyperparathyroidism | Normocalcemic hyperparathyroidism
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00066Alendronic acid0.000462%
BADD_D00100Ambrisentan0.000265%
BADD_D00165Aripiprazole--
BADD_D00284Bortezomib0.000112%
BADD_D00337Calcitriol0.000335%
BADD_D00520Colestilan chloride--
BADD_D00858Everolimus--
BADD_D00979Furosemide0.000014%
BADD_D01242Lamivudine0.001012%
BADD_D01250Lasofoxifene--
BADD_D01285Levothyroxine0.000005%
BADD_D01303Lithium carbonate0.010708%
BADD_D01304Lithium cation0.005223%
BADD_D01305Lithium hydroxide--
BADD_D01567Nilotinib0.000336%
BADD_D01676Paricalcitol--
BADD_D01951Risperidone0.000121%
BADD_D02105Tacrolimus0.000446%
BADD_D02170Testosterone--
BADD_D02174Testosterone undecanoate--
BADD_D02218Tiludronate disodium--
BADD_D02325Valdecoxib--
BADD_D02392Zoledronic acid0.002863%
BADD_D02434Cinacalcet0.002424%
BADD_D02464Fingolimod0.000530%
The 1th Page    1    Total 1 Pages
ADReCS-Target
ADR Term Drug Name Target